Cell and Gene Therapy Market - Insights for Business Growth Report 2024-2032

Cell and Gene Therapy Market Synopsis:

Cell and Gene Therapy Market Size Was Valued at USD 25.31 Billion in 2023, and is Projected to Reach USD 270.64 Billion by 2032, Growing at a CAGR of 30.12% From 2024-2032.

The Cell and Gene Therapy Market is experiencing rapid growth, driven by advancements in biotechnology and increasing investments in innovative treatment modalities. Cell therapy involves the administration of live cells to patients for therapeutic purposes, while gene therapy focuses on correcting defective genes to treat or prevent diseases. Together, these therapies are transforming the landscape of healthcare, particularly for genetic disorders, cancers, and chronic diseases, where traditional treatment options may fall short. The surge in clinical trials and the approval of several groundbreaking therapies have highlighted the potential of cell and gene therapies to provide long-lasting and curative solutions, making them a focal point for pharmaceutical companies and research institutions alike.

A significant driver of market growth is the rising prevalence of genetic disorders and the expanding applications of these therapies across various therapeutic areas, including oncology, rare diseases, and regenerative medicine. Technological advancements, such as CRISPR and other gene-editing tools, have enhanced the precision and efficacy of gene therapies, while innovations in cell sourcing, manufacturing, and delivery methods are making cell therapies more accessible. Furthermore, supportive regulatory frameworks and increased collaboration between public and private sectors are accelerating the development and commercialization of these therapies, leading to a broader acceptance within the healthcare system.

Regionally, North America is expected to maintain a dominant position in the Cell and Gene Therapy Market, driven by a strong presence of leading biotechnology firms, robust healthcare infrastructure, and significant funding for research and development. However, the Asia-Pacific region is emerging as a vital player, with growing investments in healthcare infrastructure, increasing awareness of advanced therapies, and a rising patient population. As the market continues to expand, the focus on improving patient outcomes and reducing healthcare costs will likely drive further innovation, making cell and gene therapies a critical component of future healthcare strategies.

Cell and Gene Therapy Market Trend Analysis:

Growing Adoption of Personalized Medicine

• One prominent trend in the Cell and Gene Therapy Market is the increasing adoption of personalized medicine approaches. As therapies become more tailored to individual genetic profiles, there is a shift towards using genetic information to guide treatment decisions. This trend is particularly evident in oncology, where gene therapies are developed based on the specific mutations present in a patient’s tumor. Personalized cell therapies, such as CAR-T cell therapy, demonstrate improved efficacy and reduced side effects compared to traditional treatments. The growing emphasis on personalized medicine not only enhances patient outcomes but also drives demand for innovative gene editing technologies and bespoke therapeutic solutions.

Advances in Manufacturing and Delivery Technologies

• Another significant trend is the advancement of manufacturing and delivery technologies, which are crucial for the scalability and efficacy of cell and gene therapies. Innovations in bioprocessing techniques, such as automated cell culture systems and closed-system manufacturing, are improving the efficiency, consistency, and quality of cell products. Additionally, novel delivery methods, including viral vectors, lipid nanoparticles, and electroporation, are being developed to enhance gene transfer and expression in target cells. These technological advancements are addressing challenges related to cost, accessibility, and safety, thereby facilitating the wider adoption of cell and gene therapies in clinical settings and expanding their applications across various therapeutic areas.

Cell and Gene Therapy Market Segment Analysis:

Cell and Gene Therapy Market is Segmented on the basis of Product, Application, End User, and Region

By Product, Gene Therapy segment is expected to dominate the market during the forecast period

• In the Cell and Gene Therapy Market, products are primarily categorized into two segments: cell therapy and gene therapy, each contributing significantly to market growth and innovation. Cell therapy involves the use of living cells to treat diseases, with applications ranging from hematopoietic stem cell transplants for blood disorders to advanced therapies like CAR-T cell therapy for certain types of cancer. This segment is gaining traction due to its potential to regenerate damaged tissues and restore normal function. Conversely, gene therapy focuses on correcting or replacing defective genes to treat or prevent diseases, with applications including genetic disorders, cancers, and viral infections. The rising prevalence of these conditions and ongoing advancements in technology are driving the demand for both cell and gene therapies, leading to a dynamic market environment where research and clinical applications continue to expand. As these therapies evolve, they hold the promise of offering more effective, targeted, and long-lasting solutions to patients with previously hard-to-treat conditions.

By End User, Wound Care Centers segment expected to held the largest share

• In the Cell and Gene Therapy Market, the segmentation by end user reveals a diverse landscape, with hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and other healthcare facilities playing pivotal roles in the administration and management of these advanced therapies. Hospitals are the primary end users, equipped with the necessary infrastructure and skilled personnel to deliver complex cell and gene therapies, particularly for patients with serious genetic disorders and cancers. Ambulatory surgical centers are also increasingly adopting these therapies due to their ability to provide specialized care in a more accessible setting. Cancer care centers are critical in administering targeted gene therapies and immunotherapies, reflecting the rising focus on personalized treatment approaches. Wound care centers are leveraging regenerative cell therapies to enhance healing and recovery in patients with chronic wounds. As the demand for innovative treatment options continues to grow, the collaboration among these end users will be essential in optimizing patient care and expanding the reach of cell and gene therapies across various healthcare settings.

Cell and Gene Therapy Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America is expected to dominate the Cell and Gene Therapy Market over the forecast period, driven by a robust healthcare ecosystem characterized by extensive research funding, a strong presence of leading biotechnology and pharmaceutical companies, and a favorable regulatory environment for advanced therapies. The region benefits from significant investments in clinical research and development, which have led to the successful commercialization of several innovative gene and cell therapies. Furthermore, the rising prevalence of genetic disorders and cancers, coupled with an increasing demand for personalized medicine, is propelling the adoption of these therapies among healthcare providers and patients. As advancements in technology and manufacturing processes continue to enhance the efficacy and accessibility of cell and gene therapies, North America is poised to maintain its leadership in this rapidly evolving market.

Active Key Players in the Cell and Gene Therapy Market:

• Biogen Inc. (U.S.)
• Novartis AG (Switzerland)
• Gilead Sciences (U.S.)
• Ionis Pharmaceuticals Inc. (U.S.)
• Alnylam Pharmaceuticals Inc. (U.S.)
• Arrowhead Pharmaceuticals Inc. (U.S.)
• Spark Therapeutics (U.S.)
• Bluebird Bio Inc. (U.S.)
• RegenexBio (U.S.)
• Mesoblast Limited (Australia)
• Biocon (India), Cipla (India)
• Stempeutics Research Pvt. Ltd. (India),
• EdiGene Inc. (China),
• Immunochina (China),
• Takara Bio (Japan),
• Daiichi Sankyo Company (Japan),
• Ultragenyx Pharmaceutical Inc. (U.S.),
• Mitsubishi Tanabe Pharma (Japan),
• Oxford Biomedica plc (U.K.),
• Santen Pharmaceutical Co. (Japan),
• Therapeutic Innovation Australia (Australia),
• Merck (Germany), GenScript (China),
• Cellular Biomedicine Group (U.S.),
• GE Healthcare (U.S.),
• inStem (India),
• Lonza (Switzerland),
• Nikon CeLL innovation Co. Ltd. (Japan),
• Bristol-Myers Squibb (U.S.),
• Amgen (U.S.),
• Pfizer (U.S.),
• Kite Pharma (U.S.),
• Oxford BioTherapeutics (U.K.),
• Freeline Therapeutics (U.K.),
• PsiOxus Therapeutics (U.K.),
• Herantis Pharma Plc (Finland),
• AstraZeneca (U.K.)
• Other Active Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Cell and Gene Therapy Market by Product
 4.1 Cell and Gene Therapy Market Snapshot and Growth Engine
 4.2 Cell and Gene Therapy Market Overview
 4.3 Cell Therapy
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Cell Therapy: Geographic Segmentation Analysis
 4.4 Gene Therapy
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Gene Therapy: Geographic Segmentation Analysis

Chapter 5: Cell and Gene Therapy Market by Application
 5.1 Cell and Gene Therapy Market Snapshot and Growth Engine
 5.2 Cell and Gene Therapy Market Overview
 5.3 Oncology
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Oncology: Geographic Segmentation Analysis
 5.4 Neurological Disorders
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Neurological Disorders: Geographic Segmentation Analysis
 5.5 Other Applications
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Other Applications: Geographic Segmentation Analysis

Chapter 6: Cell and Gene Therapy Market by End User
 6.1 Cell and Gene Therapy Market Snapshot and Growth Engine
 6.2 Cell and Gene Therapy Market Overview
 6.3 Hospitals
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospitals: Geographic Segmentation Analysis
 6.4 Ambulatory Surgical Centers
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Ambulatory Surgical Centers: Geographic Segmentation Analysis
 6.5 Cancer Care Centers
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Cancer Care Centers: Geographic Segmentation Analysis
 6.6 Wound Care Centers
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Wound Care Centers: Geographic Segmentation Analysis
 6.7 Other End-Users
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Other End-Users: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Cell and Gene Therapy Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions  
 7.2 BIOGEN INC. (U.S.)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 NOVARTIS AG (SWITZERLAND)
 7.4 GILEAD SCIENCES (U.S.)
 7.5 IONIS PHARMACEUTICALS INC. (U.S.)
 7.6 ALNYLAM PHARMACEUTICALS INC. (U.S.)
 7.7 ARROWHEAD PHARMACEUTICALS INC. (U.S.)
 7.8 SPARK THERAPEUTICS (U.S.)
 7.9 BLUEBIRD BIO INC. (U.S.)
 7.10 REGENEXBIO (U.S.)
 7.11 MESOBLAST LIMITED (AUSTRALIA)
 7.12 BIOCON (INDIA)
 7.13 CIPLA (INDIA)
 7.14 STEMPEUTICS RESEARCH PVT. LTD. (INDIA)
 7.15 EDIGENE INC. (CHINA)
 7.16 IMMUNOCHINA (CHINA)
 7.17 TAKARA BIO (JAPAN)
 7.18 DAIICHI SANKYO COMPANY (JAPAN)
 7.19 ULTRAGENYX PHARMACEUTICAL INC. (U.S.)
 7.20 MITSUBISHI TANABE PHARMA (JAPAN)
 7.21 OXFORD BIOMEDICA PLC (U.K.)
 7.22 SANTEN PHARMACEUTICAL CO. (JAPAN)
 7.23 THERAPEUTIC INNOVATION AUSTRALIA (AUSTRALIA)
 7.24 MERCK (GERMANY)
 7.25 GENSCRIPT (CHINA)
 7.26 CELLULAR BIOMEDICINE GROUP (U.S.)
 7.27 GE HEALTHCARE (U.S.)
 7.28 INSTEM (INDIA)
 7.29 LONZA (SWITZERLAND)
 7.30 NIKON CELL INNOVATION CO. LTD. (JAPAN)
 7.31 BRISTOL-MYERS SQUIBB (U.S.)
 7.32 AMGEN (U.S.)
 7.33 PFIZER (U.S.)
 7.34 KITE PHARMA (U.S.)
 7.35 OXFORD BIOTHERAPEUTICS (U.K.)
 7.36 FREELINE THERAPEUTICS (U.K.)
 7.37 PSIOXUS THERAPEUTICS (U.K.)
 7.38 HERANTIS PHARMA PLC (FINLAND)
 7.39 ASTRAZENECA (U.K.)
 7.40 OTHER ACTIVE PLAYERS

Chapter 8: Global Cell and Gene Therapy Market By Region
 8.1 Overview
 8.2. North America Cell and Gene Therapy Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Product
  8.2.4.1 Cell Therapy
  8.2.4.2 Gene Therapy
  8.2.5 Historic and Forecasted Market Size By Application
  8.2.5.1 Oncology
  8.2.5.2 Neurological Disorders
  8.2.5.3 Other Applications
  8.2.6 Historic and Forecasted Market Size By End User
  8.2.6.1 Hospitals
  8.2.6.2 Ambulatory Surgical Centers
  8.2.6.3 Cancer Care Centers
  8.2.6.4 Wound Care Centers
  8.2.6.5 Other End-Users
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Cell and Gene Therapy Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Product
  8.3.4.1 Cell Therapy
  8.3.4.2 Gene Therapy
  8.3.5 Historic and Forecasted Market Size By Application
  8.3.5.1 Oncology
  8.3.5.2 Neurological Disorders
  8.3.5.3 Other Applications
  8.3.6 Historic and Forecasted Market Size By End User
  8.3.6.1 Hospitals
  8.3.6.2 Ambulatory Surgical Centers
  8.3.6.3 Cancer Care Centers
  8.3.6.4 Wound Care Centers
  8.3.6.5 Other End-Users
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Russia
  8.3.7.2 Bulgaria
  8.3.7.3 The Czech Republic
  8.3.7.4 Hungary
  8.3.7.5 Poland
  8.3.7.6 Romania
  8.3.7.7 Rest of Eastern Europe
 8.4. Western Europe Cell and Gene Therapy Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Product
  8.4.4.1 Cell Therapy
  8.4.4.2 Gene Therapy
  8.4.5 Historic and Forecasted Market Size By Application
  8.4.5.1 Oncology
  8.4.5.2 Neurological Disorders
  8.4.5.3 Other Applications
  8.4.6 Historic and Forecasted Market Size By End User
  8.4.6.1 Hospitals
  8.4.6.2 Ambulatory Surgical Centers
  8.4.6.3 Cancer Care Centers
  8.4.6.4 Wound Care Centers
  8.4.6.5 Other End-Users
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 The Netherlands
  8.4.7.5 Italy
  8.4.7.6 Spain
  8.4.7.7 Rest of Western Europe
 8.5. Asia Pacific Cell and Gene Therapy Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Product
  8.5.4.1 Cell Therapy
  8.5.4.2 Gene Therapy
  8.5.5 Historic and Forecasted Market Size By Application
  8.5.5.1 Oncology
  8.5.5.2 Neurological Disorders
  8.5.5.3 Other Applications
  8.5.6 Historic and Forecasted Market Size By End User
  8.5.6.1 Hospitals
  8.5.6.2 Ambulatory Surgical Centers
  8.5.6.3 Cancer Care Centers
  8.5.6.4 Wound Care Centers
  8.5.6.5 Other End-Users
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Cell and Gene Therapy Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Product
  8.6.4.1 Cell Therapy
  8.6.4.2 Gene Therapy
  8.6.5 Historic and Forecasted Market Size By Application
  8.6.5.1 Oncology
  8.6.5.2 Neurological Disorders
  8.6.5.3 Other Applications
  8.6.6 Historic and Forecasted Market Size By End User
  8.6.6.1 Hospitals
  8.6.6.2 Ambulatory Surgical Centers
  8.6.6.3 Cancer Care Centers
  8.6.6.4 Wound Care Centers
  8.6.6.5 Other End-Users
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkiye
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Cell and Gene Therapy Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Product
  8.7.4.1 Cell Therapy
  8.7.4.2 Gene Therapy
  8.7.5 Historic and Forecasted Market Size By Application
  8.7.5.1 Oncology
  8.7.5.2 Neurological Disorders
  8.7.5.3 Other Applications
  8.7.6 Historic and Forecasted Market Size By End User
  8.7.6.1 Hospitals
  8.7.6.2 Ambulatory Surgical Centers
  8.7.6.3 Cancer Care Centers
  8.7.6.4 Wound Care Centers
  8.7.6.5 Other End-Users
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research